Miltenyi Biomedicine’s Zamto-cel Outperforms Chemoimmunotherapy in Pivotal Lymphoma Trial
Kuala lumpur: Miltenyi Biomedicine, a clinical-stage biopharmaceutical company, reported pivotal results from the DALY 2-EU Phase II trial evaluating its CAR-T therapy zamtocabtagene autoleucel (zamto-cel) in transplant-ineligible patients with second-line relapsed or refractory large B-cell lymphoma. Announced at the 67th